Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service

Five Prime Therapeutics Presents Initial Safety Data from the Phase 1 Trial of FPT155 at the Society for Immunotherapy of Cancer Annual Meeting


Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today presented initial safety data from the Phase 1 clinical trial of FPT155 in patients with advanced solid tumors in a poster presentation at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting in National Harbor, Maryland. The poster can be found on the Publications Page of the Five Prime Therapeutics website.

"FPT155 is a first-in-class CD80 fusion protein with potential dual mechanisms to activate T cells," said Helen Collins, M.D., Executive Vice President and Chief Medical Officer of Five Prime Therapeutics. "Importantly, the initial safety results for FPT155 suggest that it may not cause the same safety issues seen with a prior molecule targeting CD28. This allows us to continue enrolling patients to study additional dose escalation cohorts and identify a dose for future studies."

The FPT155 data presented at SITC included initial safety results from the Phase 1a dose escalation portion of the trial, which is designed to characterize the safety and pharmacokinetic (PK)/pharmacodynamic (PD) profile of FPT155 and identify a recommended dose for the Phase 1b portion of the trial. This included data from 15 patients with solid tumors that were treated with FPT155 at doses of 0.07 mg, 0.21 mg, 0.7 mg, 2.1 mg, 7 mg, 21 mg, and 42 mg. The key highlights from the presentation include:

The Phase 1a/1b open-label, multicenter, dose escalation, dose exploration and dose expansion study will evaluate the safety and tolerability of FPT155 in patients with advanced solid tumors. The Phase 1a dose escalation portion of the trial will characterize the safety and PK/PD profile of FPT155 and will identify a recommended dose for the Phase 1b portion of the trial. The Phase 1b portion of the trial is intended to further characterize the safety, PK/PD profile, and preliminary efficacy of FPT155.

About FPT155

FPT155 is a first-in-class CD80 fusion protein that (i) directly engages CD28 to enhance its co-stimulatory T-cell activation activity without inducing super agonism, and (ii) blocks CTLA-4 from competing for endogenous CD80, allowing CD28 signaling to prevail in T-cell activation in the tumor microenvironment. FPT155 has also demonstrated its ability to retain anti-tumor activity independent of its engagement with CTLA-4, suggesting a differentiated mechanism of action from CTLA-4-blocking antibodies. Studies in preclinical models suggest FPT155 has the potential to be a potent T-cell co-stimulator with strong monotherapy anti-tumor activity.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc. develops innovative protein therapeutics to improve the lives of patients with cancer. The company focuses on developing immune modulators and precision therapies for solid tumor cancers paired with companion diagnostics to identify patients who are most likely to benefit from treatment with Five Prime's product candidates. The company's product candidates have innovative mechanisms of action and address patient populations in need of better therapies. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.

Cautionary Note on Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Five Prime's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Five Prime's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Five Prime assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Source: Five Prime Therapeutics, Inc.


These press releases may also interest you

at 19:05
FOR EU TRADE AND MEDICAL MEDIA ONLY. NOT FOR DISTRIBUTION IN BENELUX. The Janssen Pharmaceutical Companies of Johnson & Johnson announced yesterday interim results from the CHRYSALIS study (NCT02609776) evaluating amivantamab, a fully human...

at 18:56
Changhong(Shanghai: 600839), one of the leading home appliance manufacturers in China, signed an agreement with China National Badminton Team at a signing ceremony held in Chengdu, Sichuan Province, on September 16, to become the official sponsor of...

at 18:03
On September 20, 2020, Guangzhou-based company Guoyao Tech announced a roadmap to complete a prototype launch of 10 kg by 2022 and short-range tonnage launch by electromagnetic by 2023. The company is developing a novel launch system - based on...

at 15:00
Positron, a leading provider of XR Cinema systems, known for its acclaimed Voyager® VR motion chair, announced today the launch of a global intellectual licensing program. The Positron IP Licensing program will make available the patents, designs and...

at 15:00
Last week, at Demand Gen Summit 2020, conversation marketing optimization company ChatFunnels announced the winners of the 2020 Demand Gen Awardstm. The award identifies outstanding individuals in the sales and marketing industry that have driven...

at 14:01
Eli Lilly and Company today announced Verzenio® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) significantly decreased the risk of breast cancer recurrence by 25 percent compared to standard adjuvant ET alone for people...



News published on 9 november 2019 at 07:05 and distributed by: